Pfizer Ltd

- No significant new fundraising through debt or equity is planned. - CAPEX plan for the next year includes only regular operational expenditures amounting to a few crores. - The company is not engaging in major CAPEX spending. - Discussions about land sales (Thane land) are ongoing but not directly related to fundraising. - Overall, there is no indication of major debt or equity raising activities in the near future.

- No major capital expenditure (CAPEX) planned for the next year; only regular operational CAPEX of a few crores. - No significant new investments except for pediatric vaccinations. - Investments are primarily directed towards the operating model rather than fixed asset expansion. - Focus on creating new accessibility points for vaccination, including setting up vaccination centers and home vaccination services, representing strategic shifts rather than heavy capital outlays. - Discussions ongoing regarding Thane land sale; received part transfer approval but evaluating options before proceeding. - Overall, the company is cautious with CAPEX, emphasizing operational efficiency and market access over large-scale capital investments.

- New product sales were around Rs.170 crores last year, with a few new products lined up; specific therapeutic segments and revenue contributions are not disclosed yet. (Page 32) - Established (internal medicine) business showed a strong 12%-13% growth in Q1 and is expected to sustain momentum with a new operating structure. (Page 14) - Adult vaccination has high double-digit growth potential with a significant future focus, driven by increased awareness post-COVID. (Page 13) - Hospital business is under pressure due to COVID but may expand by increasing account reach and leveraging innovative anti-infectives like Zavicefta and Zinforo. (Page 29) - Vaccination business expected to rebound to pre-COVID levels soon; digital campaigns underway to encourage immunization. (Pages 24, 8) - Overall revenue affected by COVID in Q1 but company expects gradual recovery through 2021 with digital and operational adaptations. (Pages 6, 8)

- EBITDA margin is expected to normalize to around 25%-30% from the current elevated 37% seen during COVID-related cost savings; maintaining 37% going forward is unlikely. - Profit after tax grew 10% YoY in Q1 FY21 but future growth is uncertain due to COVID impacts and market conditions. - Management refrains from precise future growth predictions, especially for established business segments. - New product launches are planned, but specific revenue contributions and therapeutic areas are not disclosed yet. - Operating expenses and promotional spends are expected to increase as normalcy returns, likely dampening margins. - Digital initiatives and evolving sales models may improve efficiency but impact on earnings remains unquantified. - Overall, earnings growth is cautiously optimistic but moderated by competitive pressures and pandemic uncertainties.

The transcript does not provide specific details on the current or expected order book or pending orders for Pfizer Limited. However, relevant insights include: - Hospital and vaccines business sales were impacted due to COVID-19, affecting the order flow with almost 41% decline in hospital revenue. - Recovery in hospital business is expected to be gradual due to ICU capacity constraints. - Vaccine demand is expected to recover to pre-COVID levels in the near future. - Elective surgeries and other hospital services remain constrained, limiting immediate order inflow. - Established internal medicine portfolio showed healthy growth of 12.8%. - No explicit mention of concrete order book or pending orders numbers was made during the call. - Business outlook depends heavily on external COVID-19 situation, making forecasting difficult. Overall, Pfizer anticipates gradual improvement but no detailed quantitative order book data is disclosed.